BioPharmSignal logoBioPharmSignal

Biotech News

PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights

PMV Pharmaceuticals (PMVP)PMV PharmaceuticalsEarnings

Rezatapopt granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of TP53 Y220C positive ovarian cancer New England Journal of Medicine published first-in-human rezatapopt data showing selective reactivation of mutant p53 in advanced solid tumors Rezatapopt New

Related news

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

REPLReplimune Group2026-08-14 12:00 EST

Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

ENTAEnanta Pharmaceuticals2026-08-10 20:01 EST

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

View all latest news

PMV Pharmaceuticals

Mutant-p53 Precision Oncology PMV Pharmaceuticals develops small-molecule precision therapies that target specific mutations in the p53 tumor-suppressor protein. Its platform is designed to restore the normal cancer-suppressing function of structurally altered p53 proteins, addressing mutations found across multiple solid-tumor...

Recent company news

PMVPPMV Pharmaceuticals2026-09-08 12:00 EST

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

PMVPPMV Pharmaceuticals2026-09-01 03:04 EST

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PMVPPMV Pharmaceuticals2026-08-31 20:02 EST

PMV Pharma Announces Proposed Public Offering of Securities

PMVPPMV Pharmaceuticals2026-08-31 20:01 EST

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

PMVPPMV Pharmaceuticals2026-08-14 12:00 EST

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

Stock data

Close
1.48 USD
Market cap
62.93M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States